inclusion criteria: age 1. are ≥18 years of age at the time of randomization disease characteristics 2. are currently not hospitalized 3. have one or more mild or moderate covid-19 symptoms: i. fever ii. cough iii. sore throat iv. malaise v. headache vi. muscle pain vii. gastrointestinal symptoms, or viii. shortness of breath with exertion 4. must have sample collection for first positive sars-cov-2 viral infection determination ≤3 days prior to start of the inhalation. sex 5. are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in section 10.4, appendix 4. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures 6. understand and agree to comply with planned study procedures 7. agree to the collection of nasopharyngeal swabs and venous blood informed consent 8. the participant or legally authorized representative gives signed informed consent as described in section 14.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: age 1. are ≥18 years of age at the time of randomization disease characteristics 2. are currently not hospitalized 3. have one or more mild or moderate covid-19 symptoms: i. fever ii. cough iii. sore throat iv. malaise v. headache vi. muscle pain vii. gastrointestinal symptoms, or viii. shortness of breath with exertion 4. must have sample collection for first positive sars-cov-2 viral infection determination ≤3 days prior to start of the inhalation. sex 5. are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in section 10.4, appendix 4. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures 6. understand and agree to comply with planned study procedures 7. agree to the collection of nasopharyngeal swabs and venous blood informed consent 8. the participant or legally authorized representative gives signed informed consent as described in section 14.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: age are ≥18 years of age at the time of randomization disease characteristics are currently not hospitalized have one or more mild or moderate covid-19 symptoms: i. fever ii. cough iii. sore throat iv. malaise v. headache vi. muscle pain vii. gastrointestinal symptoms, or viii. shortness of breath with exertion must have sample collection for first positive sars-cov-2 viral infection determination ≤3 days prior to start of the inhalation. sex are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in section 10.4, appendix 4. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures understand and agree to comply with planned study procedures agree to the collection of nasopharyngeal swabs and venous blood informed consent the participant or legally authorized representative gives signed informed consent as described in section 14.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: age are ≥18 years of age at the time of randomization disease characteristics are currently not hospitalized have one or more mild or moderate covid-19 symptoms: i. fever ii. cough iii. sore throat iv. malaise v. headache vi. muscle pain vii. gastrointestinal symptoms, or viii. shortness of breath with exertion must have sample collection for first positive sars-cov-2 viral infection determination ≤3 days prior to start of the inhalation. sex are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in section 10.4, appendix 4. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures understand and agree to comply with planned study procedures agree to the collection of nasopharyngeal swabs and venous blood informed consent the participant or legally authorized representative gives signed informed consent as described in section 14.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.